Ro

Telehealth company connecting patients with US-licensed professionals for weight loss, sexual health, hair loss, and more.

Website: https://ro.co/

Cover Block

PUBLIC

Field Value
Name Ro
Tagline Telehealth company connecting patients with US-licensed professionals for weight loss, sexual health, hair loss, and more.
Headquarters New York City, United States
Founded 2017
Stage Series D+
Business Model Direct-to-Consumer (DTC)
Industry Healthtech
Technology Type Software (Non-AI)
Geography North America
Growth Profile Venture Scale
Funding Label Series D+
Total Disclosed ~$1.03B

Links

PUBLIC

Executive Summary

PUBLIC

Ro is a direct-to-patient telehealth company that has built a vertically integrated stack of online consultations, diagnostics, labs, and pharmacy fulfillment, and the GLP-1 weight loss wave has put its consumer health franchise back at the center of investor attention [Built In NYC, Unknown] [Sacra, Unknown]. Founded in 2017 by Zachariah Reitano, Rob Schutz, and Saman Rahmanian, the company began with the Roman brand for erectile dysfunction and has since expanded into hair loss, fertility, skincare, and weight management under the Ro Body banner [Wikipedia, Unknown] [Ro, Unknown]. Differentiation rests on owning the full patient journey end-to-end rather than acting purely as a prescription marketplace: Ro pairs licensed providers with its own pharmacy and in-home phlebotomy network, a configuration that the company describes as the only nationwide combination of telehealth, labs, and pharmacy [Built In NYC, Unknown]. Capitalization is heavy, with roughly $1.03B disclosed across Series C and D rounds led by General Catalyst and ShawSpring, signalling investor conviction in a multi-condition consumer health platform [VC News Daily, Unknown] [Tracxn, Unknown]. Recent commercial signals include a March 2026 collaboration with Novo Nordisk that gives cash-pay patients up to $1,200 per year in savings on Wegovy, and the addition of Eli Lilly's Foundayo to the GLP-1 menu [Ro, March 2026] [PR Newswire, Unknown]. Reported GLP-1 revenue of roughly $370M in 2024 suggests the weight loss line is now the company's commercial center of gravity [Sacra, Unknown]. Over the next 12 to 18 months, the questions that matter are GLP-1 supply stability, the durability of cash-pay pricing as branded supply normalizes, and whether Ro can extend its membership economics beyond weight loss into recurring categories like fertility and dermatology.

Data Accuracy: GREEN -- Confirmed by Ro press releases, VC News Daily, Built In NYC, and Sacra.

Taxonomy Snapshot

Axis Value
Stage Series D+
Business Model Direct-to-Consumer (DTC)
Industry / Vertical Healthtech / Telehealth
Technology Type Software (Non-AI)
Geography North America (United States)
Growth Profile Venture Scale
Funding ~$1.03B disclosed across Series C and Series D rounds

Company Overview

PUBLIC

Ro was founded in 2017 in New York City by Zachariah Reitano, Rob Schutz, and Saman Rahmanian, initially under the Roman brand focused on men's sexual health [Wikipedia, Unknown] [Initialized Capital, Unknown]. The founding insight, recounted by Reitano in a 2023 founder spotlight, was that a meaningful share of consumer health conditions could be diagnosed and managed through a structured online intake plus licensed-provider review, removing the friction of in-person visits for stigmatized or routine concerns [Initialized Capital, Unknown]. From the original ED franchise, the company added hair loss (Roman), then expanded the corporate brand to Ro and built additional verticals in fertility, dermatology, and weight management [Ro, Unknown].

The company is headquartered in New York and describes itself as a direct-to-patient healthcare company offering nationwide telehealth, in-home care, diagnostics, labs, and pharmacy services [Built In NYC, Unknown] [ZoomInfo, Unknown]. Key milestones include the $200M Series C in July 2020 led by General Catalyst, the $500M Series D in March 2021 also led by General Catalyst, and a further $150M Series D extension in February 2022 led by ShawSpring [Ro, July 27, 2020] [Ro, March 23, 2021] [Tracxn, Unknown]. More recent product milestones include the launch of compounded ED treatments Daily Rise gummies and Sparks, the Ro Body weight loss program built around GLP-1 medications, and the March 2026 Novo Nordisk savings collaboration on Wegovy [Wikipedia, Unknown] [PR Newswire, Unknown] [Ro, March 2026].

Governance has matured alongside scale: Margo Georgiadis, formerly CEO of Ancestry.com, joined Ro's board of directors, adding consumer subscription experience at the board level [Wikipedia, Unknown].

Data Accuracy: GREEN -- Confirmed by Ro press releases, Wikipedia, Initialized Capital, and Built In NYC.

Product and Technology

MIXED

Ro's product surface is a portfolio of condition-specific consumer brands sitting on a shared clinical, pharmacy, and logistics backbone [PUBLIC]. On the consumer side, the company offers treatment for weight loss, sexual health, hair loss, fertility, skincare, and erectile dysfunction, marketed under names that include Roman, Ro Derm, Ro Fertility, and Ro Body [Ro, Unknown]. The Ro Body weight loss program packages GLP-1 medications with lab testing, one-to-one coaching, and personalized provider care, and is priced at $39 for the first month and as low as $74 per month on an annual prepay [PR Newswire, Unknown] [Ro, Unknown]. In ED, the company has rolled out compounded formulations branded as Daily Rise gummies and Sparks, an attempt to differentiate beyond generic sildenafil and tadalafil on format and experience [Wikipedia, Unknown] [Ro, Unknown].

Underneath the brands, the operational claim is integration: nationwide telehealth, in-home care, diagnostics, labs, and pharmacy services on one platform [Built In NYC, Unknown] [ZoomInfo, Unknown]. For weight management specifically, that means the patient flow can include a virtual visit, lab work performed at home, GLP-1 prescription dispensed through Ro's own pharmacy, ongoing coaching, and an insurance concierge that pursues coverage where available [Ro, Unknown]. The March 2026 Novo Nordisk collaboration extends this to cash-pay savings on branded Wegovy, with up to $1,200 per year in savings on the pen and $600 per year on the pill via 3, 6, and 12 month prepaid plans [Ro, March 2026].

On the technology stack, public detail is limited, but open engineering roles point to a cloud-native infrastructure with Kubernetes workloads, SOC 2, HIPAA, and HITRUST compliance regimes, and active investment in identity and privacy engineering (inferred from job postings) [PRIVATE] [Built In, Unknown] [Ro, Unknown]. The company is currently hiring a Staff Software Engineer for Identity and Privacy and a Manager of Training and Quality Assurance in Customer Experience, suggesting continued spend on platform security and on the human side of clinical operations [Ro, Unknown].

Data Accuracy: GREEN -- Confirmed by Ro website, PR Newswire, and Built In.

Market Research and Opportunity

PUBLIC

The consumer telehealth category has been reshaped in the last 24 months by the arrival of GLP-1 weight loss medications as a mass-market consumer health product, and Ro sits in the middle of that shift. No third-party TAM figure is cited in the structured research for the U.S. consumer telehealth or GLP-1 markets, so this section avoids unsourced sizing. What is in evidence is concrete: Sacra reports Ro generated approximately $370M in GLP-1 revenue in 2024, a figure large enough to suggest GLP-1s have moved from a product line to the dominant commercial vector for the company [Sacra, Unknown].

Demand drivers visible in the cited material include the structural shift of branded GLP-1 manufacturers toward direct-to-consumer cash-pay channels, exemplified by Novo Nordisk's collaboration with Ro on Wegovy savings and Eli Lilly making Foundayo available through the platform [Ro, March 2026] [PR Newswire, Unknown]. These partnerships matter because they signal that pharma incumbents view DTC telehealth as a legitimate distribution layer for branded obesity care rather than a parallel grey market built on compounding. Clinically, Ro cites average weight loss of 11 to 20 percent over one year for patients on its program, against roughly 2 to 3 percent for diet and exercise alone, a gap that supports continued consumer pull [Ro, Unknown].

Adjacent and substitute markets include traditional in-person obesity medicine clinics, employer benefit programs run through carriers like Omada and Virta, and competing DTC telehealth players. Regulatory and macro forces to watch include the FDA's posture on compounded GLP-1s now that branded supply has normalized, state-by-state telehealth prescribing rules, and any payer-side moves to broaden or restrict coverage of GLP-1s for obesity (as opposed to diabetes).

Metric Value Source
Ro GLP-1 revenue, 2024 ~$370M [Sacra, Unknown]
Average 1-year weight loss on Ro program 11-20% [Ro, Unknown]
Wegovy pen savings via Novo Nordisk collaboration up to $1,200 / year [Ro, March 2026]
Ro Body membership entry price $39 first month, $74/mo annual [Ro, Unknown]

The takeaway: the cited data points concentrate around weight loss economics rather than the legacy ED and hair loss franchises, which is consistent with GLP-1s having become the central revenue line and the central strategic question for the next 18 months.

Data Accuracy: YELLOW -- Sacra revenue figure is single-source ORANGE; Ro and Novo Nordisk product and pricing data are GREEN.

Competitive Landscape

MIXED

Ro competes against a small set of well-funded DTC telehealth peers and a much larger set of category-specific challengers, and its differentiation rests on owning more of the stack than most.

Company Positioning Stage / Funding Notable Differentiator Source
Ro Multi-category DTC telehealth with owned pharmacy, labs, and in-home care Series D+, ~$1.03B disclosed Nationwide integration of telehealth, labs, and pharmacy; branded GLP-1 partnerships with Novo Nordisk and Lilly [VC News Daily, Unknown] [Built In NYC, Unknown] [Ro, March 2026]
Hims & Hers Multi-category DTC telehealth, public company Public (NYSE: HIMS) Stronger brand marketing engine, public-market currency, broader mental health offering [Wikipedia, Unknown]
Curology DTC dermatology with custom-compounded skincare Venture-backed Vertical focus on personalized topical formulations [Wikipedia, Unknown]
Musely DTC dermatology telehealth Venture-backed Prescription skincare focused on melasma and anti-aging [Wikipedia, Unknown]
Nurx DTC telehealth focused on women's health and contraception Venture-backed Women's health vertical depth [Wikipedia, Unknown]

Segmenting the field, the closest direct analogue is Hims & Hers, which competes across the same multi-condition surface (sexual health, hair, dermatology, mental health, weight loss) and has the additional advantage of public-market visibility and a balance sheet marked to market daily. Curology, Musely, and Nurx are vertical specialists: each goes deeper than Ro in a single category (dermatology in two cases, women's health in the third) but lacks the multi-line consumer franchise. Sitting alongside both groups are employer-channel obesity and chronic care players (Omada, Virta, Teladoc-owned BetterHelp adjacent assets) that compete for the same patient through a different buyer.

Ro's defensible edge today is the combination of owned pharmacy, owned labs operations, and direct collaborations with branded GLP-1 manufacturers. The Novo Nordisk Wegovy savings program and access to Lilly's Foundayo are not trivial to replicate, because they require pharma counterparties to view the platform as a controlled, compliant channel for branded product [Ro, March 2026] [PR Newswire, Unknown]. That edge is durable to the extent that Ro can keep operating at the scale and clinical-quality bar pharma partners require, and perishable to the extent those same partners eventually sign similar deals with Hims, Amazon Pharmacy, or Costco.

The most exposed flank is brand reach versus Hims & Hers, whose marketing spend and Super Bowl-era brand presence have outpaced Ro's consumer visibility, particularly in younger cohorts. Ro also does not own an employer or payer channel of consequence, which means if obesity care shifts decisively toward benefits-funded distribution, the cash-pay consumer model becomes a smaller slice of the prize. Plausible 18-month scenario: the winner if branded GLP-1 supply remains constrained and pharma continues to favor a small number of compliant DTC channels is Ro, because its integrated stack and existing pharma relationships compound. The loser if payers move aggressively to cover GLP-1s for obesity and route patients through carrier-aligned vendors is the cash-pay DTC model broadly, which would compress both Ro and Hims margins on weight loss.

Data Accuracy: YELLOW -- Subject company data confirmed by multiple sources; competitor positioning drawn from category knowledge with single-source confirmation of named competitor list.

Opportunity

PUBLIC

If Ro executes, the prize is to become the default consumer front door for chronic, lifestyle, and stigmatized conditions in the United States, with a vertically integrated clinical and pharmacy backbone that pharma and payers route patients through.

The headline opportunity. The single largest outcome Ro could plausibly become is the dominant cash-pay consumer health platform in the U.S., spanning weight management, sexual health, dermatology, fertility, and adjacent categories, with branded pharma manufacturers using it as a primary direct channel. The evidence that this outcome is reachable rather than aspirational sits in three places: roughly $370M in 2024 GLP-1 revenue indicates real scale already exists in the largest new consumer health category in a decade [Sacra, Unknown]; the Novo Nordisk Wegovy savings collaboration and Lilly Foundayo access show that branded manufacturers will partner with Ro on terms that resemble channel agreements rather than ad placements [Ro, March 2026] [PR Newswire, Unknown]; and the integration of nationwide telehealth, labs, and pharmacy services means Ro can own the patient relationship across the full episode of care, not just the prescription [Built In NYC, Unknown].

Growth scenarios.

Scenario What happens Catalyst Why it's plausible
Branded GLP-1 channel of record Ro becomes the primary DTC channel for branded Wegovy, Zepbound, and successor obesity drugs, with multi-year pharma partnerships Expansion of the Novo Nordisk model to additional drugs and to Lilly's full GLP-1 franchise Both Novo and Lilly have already signed channel-style deals with Ro [Ro, March 2026] [PR Newswire, Unknown]
Multi-condition membership flywheel Ro Body membership economics ($39 first month, $74/mo annual prepay) extend across hair, fertility, and dermatology, lifting LTV per patient Cross-sell of existing weight loss patients into adjacent verticals using owned pharmacy and labs Membership pricing and cross-category brand portfolio (Roman, Ro Derm, Ro Fertility, Ro Body) are already in market [Ro, Unknown]
Quasi-clinical infrastructure Ro positions its nationwide labs, pharmacy, and provider network as infrastructure other healthcare brands and pharma plug into A second branded pharma partnership in a non-GLP-1 category, or a payer relationship for in-home labs Ro is described publicly as the only nationwide combination of telehealth, labs, and pharmacy services [Built In NYC, Unknown]

What compounding looks like. The flywheel is the patient relationship. A patient acquired into Ro Body for weight loss generates recurring membership revenue, lab revenue, and pharmacy fulfillment margin, and becomes addressable for hair, dermatology, sexual health, and fertility with a marginal acquisition cost close to zero. Reported clinical outcomes of 11 to 20 percent weight loss in one year support retention, since outcomes that strong reduce the natural churn that plagues consumer health subscriptions [Ro, Unknown]. The branded pharma collaborations reinforce the loop in a different direction: better savings on Wegovy improve conversion, which grows the patient base, which makes Ro a more attractive partner for the next pharma deal [Ro, March 2026].

The size of the win. A credible public comparable is Hims & Hers, the closest peer on category breadth, whose public-market valuation provides a marker for what investors will pay for a multi-category DTC telehealth franchise at scale. Translating to Ro: if the branded GLP-1 channel-of-record scenario plays out and the membership flywheel extends across categories, Ro's commercial profile would resemble or exceed that of its closest public peer (scenario, not a forecast). The downside framing, that GLP-1 economics compress as supply normalizes and payers route patients elsewhere, will be addressed in the private risk analysis.

Data Accuracy: YELLOW -- Headline opportunity grounded in GREEN-cited product, partnership, and pricing data; revenue scale anchored by single-source Sacra figure (ORANGE); scenario sizing explicitly labelled scenario rather than forecast.

Sources

PUBLIC

  1. [Ro, Unknown] Ro - Weight loss, better sex, fuller hair, improved skin and more online | https://ro.co/

  2. [Ro, Unknown] Ro - Telehealth for ED, Hair loss, Skincare, Fertility and More | https://ro.co/contact-us/

  3. [Ro, Unknown] Weight Loss - Ro Body Membership | https://ro.co/weight-loss/

  4. [Ro, Unknown] Weight Loss Program Pricing | https://ro.co/weight-loss/pricing/

  5. [Ro, Unknown] New funding, same mission | https://ro.co/news/new-funding/

  6. [Ro, March 2026] Ro Helps Patients Save up to $1,200 Per Year on Wegovy through Collaboration with Novo Nordisk | https://ro.co/press/wegovy-savings-options/

  7. [Ro, Unknown] New Research Shows Ro Helps Patients Achieve Weight Loss and Safety Outcomes Consistent with Clinical Trials | https://ro.co/press/68-week-outcomes/

  8. [Ro, July 27, 2020] Series C announcement | https://ro.co/news/new-funding/

  9. [Ro, March 23, 2021] Series D announcement | https://ro.co/news/new-funding/

  10. [VC News Daily, Unknown] Ro Completes $500M Series D Funding Round | https://vcnewsdaily.com/ro/venture-capital-funding/hwftfbdwyg

  11. [Wikipedia, Unknown] Ro (company) | https://en.wikipedia.org/wiki/Ro_(company)

  12. [Built In NYC, Unknown] Ro (Ro.co) NYC Office: Careers, Perks + Culture | https://www.builtinnyc.com/company/ro

  13. [Built In, Unknown] Ro (Ro.co) Offices and Career Growth | https://builtin.com/company/ro

  14. [ZoomInfo, Unknown] Ro - Overview, News & Similar companies | https://www.zoominfo.com/c/ro/465295896

  15. [Dealroom.co, Unknown] Ro Health company information, funding & investors | https://app.dealroom.co/companies/ro_co

  16. [Initialized Capital, Unknown] Founder Spotlight: Zachariah Reitano, Ro CEO | https://blog.initialized.com/2023/07/founder-spotlight-zachariah-reitano-ro-ceo/

  17. [PR Newswire, Unknown] Ro News and Press Releases | https://www.prnewswire.com/news/ro/

  18. [Sacra, Unknown] Ro GLP-1 revenue analysis | https://sacra.com/

  19. [Tracxn, Unknown] Ro funding history | https://tracxn.com/

  20. [Woman's World, Unknown] Ro Offers Telehealth Including Weight-Loss Medications | https://www.womansworld.com/weight-loss/glp-1/ro-co-weight-loss

Articles about Ro

View on Startuply.vc